Alerts will be sent to your verified email
Verify Email
VENMAX
|
Venmax Drugs&Pharma
|
Norris Medicines
|
Chemo Pharma Labs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-44.32 % | 47.03 % | -4.51 % |
|
5yr Avg Net Profit Margin
|
-30.94 % | -30.66 % | 0.0 |
|
Price to Book
|
3.65 | 0.0 | 1.45 |
|
P/E
|
0.0 | 0.0 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 97.28 Days | 0.0 |
|
5yr Average Interest Coverage Ratio
|
-318.36 | -1.37 | 794.39 |
|
5yr Avg ROCE
|
-45.33 % | -19.87 % | -3.17 % |
|
5yr Avg Operating Profit Margin
|
-50.41 % | -6.94 % | 0.0 |
|
5 yr average Debt to Equity
|
-0.64 | -3.0 | 0.01 |
|
5yr CAGR Net Profit
|
n/a | -15.97 % | n/a |
|
5yr Average Return on Assets
|
187.49 % | -18.92 % | -4.13 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
23.13 % | 34.0 % | 27.89 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -0.04 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Venmax Drugs&Pharma
|
Norris Medicines
|
Chemo Pharma Labs
|
|---|